Comparison the Efficacy and Safety Between 308nm LED and 308nm Excimer Light in Treatment of Psoriasis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044793

Enrollment

Unknown

Registered

2021-03-27

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis

Interventions

A:308 LED phototherapy

B:308 Excimer Light phototherapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients (aged from 18 to 70 years); 2. Stable ( >=1 year ) mild to moderate chronic plaque psoriasis; 3. with similar plaque psoriasis in left and right body; 4. Without phototherapy in the past 6 months; 5. Written informed consent is given.

Exclusion criteria

Exclusion criteria: 1.Drug induced psoriasis; 2.Other skin diseases that may influence a disease assessment; 3.With diseases of Lupus erythematosus, Xeroderma pigmentosum, solar keratosis, Bloom syndrome, Dysplastic nevus syndrome, or dermatomyositis, History of melanoma; 4.With diseases of Porphyria, cataract, pemphigus, History of family melanoma; 5.History of taking photosensitizing drugs; 6.History of photosensitive; 7.With severe comorbidities; 8.Pregnant or breastfeeding woman; 9. Biological treatment for psoriasis in the past 6 months;Systemic treatment for psoriasis in the past 1 months; Topical treatment for psoriasis in the past 2 weeks; 10.Other conditions not suitable for the study.

Design outcomes

Primary

Measure	Time frame
psoriasis area and severity index;	—

Countries

China

Contacts

Public ContactShi Yuling

Shanghai Skin Disease Hospital

shiyuling1973@tongji.edu.cn+86 13816213884

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026